(Q31055398)

28 June 2017

title

Progressive epitope-blocked panning of a phage library for isolation of human RSV antibodies (English)

1 reference

28 June 2017

1 reference

Ping Tsui

1

1 reference

28 June 2017

Mark A Tornetta

2

1 reference

28 June 2017

Robert S Ames

3

1 reference

28 June 2017

Carol Silverman

4

1 reference

28 June 2017

Terence Porter

5

1 reference

28 June 2017

Cynthia Weston

6

1 reference

28 June 2017

Sandra Griego

7

1 reference

28 June 2017

Raymond W Sweet

8

1 reference

28 June 2017

publication date

1 May 2002

1 reference

Journal of Immunological Methods

28 June 2017

published in

1 reference

28 June 2017

volume

263

1 reference

28 June 2017

issue

1-2

1 reference

28 June 2017

page(s)

123-132

1 reference

Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus

28 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

A vaccine for HIV type 1: the antibody perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

Antibody and virus: binding and neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

A directory of human germ-line V kappa segments reveals a strong bias in their usage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

Immunoprophylaxis of infections with respiratory syncytial virus: observations and hypothesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

Respiratory syncytial virus puzzle: clinical features, pathophysiology, treatment, and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

The core of the respiratory syncytial virus fusion protein is a trimeric coiled coil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

Immunity and immunopathology to respiratory syncytial virus. The mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

Antibodies in human infectious disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

Cloning and sequencing of human immunoglobulin V lambda gene segments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

Making antibodies by phage display technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

Structural characterization of the human respiratory syncytial virus fusion protein core

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2802%2900032-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-1759(02)00032-7

1 reference

28 June 2017

1 reference